These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28099271)

  • 21. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
    von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U
    J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
    Zidan MA; Kamal Shaaban HM; Elghannam DM
    Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?
    Buccisano F; Walter RB
    Curr Opin Hematol; 2017 Mar; 24(2):132-138. PubMed ID: 27930388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
    Mosna F; Papayannidis C; Martinelli G; Di Bona E; Bonalumi A; Tecchio C; Candoni A; Capelli D; Piccin A; Forghieri F; Bigazzi C; Visani G; Zambello R; Zanatta L; Volpato F; Paolini S; Testoni N; Gherlinzoni F; Gottardi M
    Am J Hematol; 2015 Jun; 90(6):515-23. PubMed ID: 25753065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current therapy for acute myeloid leukemia and acute promyelocytic leukemia].
    Miyawaki S
    Rinsho Ketsueki; 2014 Jan; 55(1):31-41. PubMed ID: 24492035
    [No Abstract]   [Full Text] [Related]  

  • 29. Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia.
    Hamadani M; Awan FT
    Hematol Oncol; 2010 Mar; 28(1):3-12. PubMed ID: 19645073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Russian experts' clinical guidelines for acute myeloid leukemia treatment in patients less than 60 years of age].
    Savchenko VG; Parovichnikova EN; Afanas'ev BV; Gritsaev SV; Semochkin SV; Bondarenko SN; Troitskaia VV; Sokolov AN; Kuz'mina LA; Kliasova GA; Baranova OIu; Lapin VA; Konstantinova TS; Samoĭlova OS; Kaporskaia TS; Shatokhin SV
    Ter Arkh; 2014; 86(7):4-13. PubMed ID: 25314772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.
    Kayser S; Feszler M; Krzykalla J; Schick M; Kramer M; Benner A; Thol F; Platzbecker U; Müller-Tidow C; Ho AD; Ehninger G; Heuser M; Schlenk RF; Thiede C; Röllig C; Krämer A
    Eur J Haematol; 2017 Dec; 99(6):544-552. PubMed ID: 28940816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.
    Hemmati PG; Schulze-Luckow A; Terwey TH; le Coutre P; Vuong LG; Dörken B; Arnold R
    Eur J Haematol; 2014 Feb; 92(2):102-10. PubMed ID: 24138573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014.
    Michaelis LC; Erba HP
    Curr Opin Hematol; 2015 Mar; 22(2):108-15. PubMed ID: 25603478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy?
    Walter RB
    Curr Opin Hematol; 2016 Mar; 23(2):102-7. PubMed ID: 26766538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission.
    Hemmati PG; Terwey TH; Na IK; le Coutre P; Jehn CF; Vuong LG; Dörken B; Arnold R
    Eur J Haematol; 2015 May; 94(5):431-8. PubMed ID: 25220715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Research on the clinical effect and in vitro study of HLA-mismatched hematopoietic stem cell infusion for acute myeloid leukemia.
    Zhang R; Zhao F; Wang J
    Hematology; 2015 Dec; 20(10):555-60. PubMed ID: 26067370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
    McMahon CM; Perl AE
    Leuk Lymphoma; 2019 Mar; 60(3):583-597. PubMed ID: 30234399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.
    Sengsayadeth S; Savani BN; Blaise D; Malard F; Nagler A; Mohty M
    Haematologica; 2015 Jul; 100(7):859-69. PubMed ID: 26130513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
    Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.